Search
Research
Echocardiographic screening for rheumatic heart disease in high and low risk Australian childrenWe aimed to establish the prevalence of RHD in high-risk Indigenous Australian children using these criteria and to compare the findings with a group of...
Research
Benzathine penicillin G for the management of RHD: Concerns about quality and access, and opportunities for intervention and improvementBenzathine penicillin G is an important antibiotic for the treatment and prevention of group A streptococcal infections associated with rheumatic fever and...
Research
A conceptual framework for comprehensive rheumatic heart disease control programsThe World Health Organization, World Heart Federation, and other organizations recommend comprehensive control programs for rheumatic fever (RF) and...
Research
Prevention of rheumatic fever and heart disease: Nepalese experienceHistorically, many young people suffered severe valvular disease and died awaiting heart valve replacement.
Research
Continued challenge of rheumatic heart disease: The gap of understanding or the gap of implementation?We still do not have a RF vaccine, although the recent announcement that the Australian and New Zealand governments are jointly sponsoring a program to fast...
Research
Position statement of the World Heart Federation on the prevention and control of rheumatic heart diseaseIn the 21st century, rheumatic fever (RF) and rheumatic heart disease (RHD) are neglected diseases of marginalized communities.
Research
Screening for rheumatic heart disease: current approaches and controversiesIn endemic areas, RHD has long been a target of screening programmes that, historically, have relied on cardiac auscultation.
Research
Acute Rheumatic Fever and Chronic Rheumatic DiseaseThis chapter describes the epidemiology, pathogenesis, clinical manifestations, diagnostic criteria, and management principles of acute rheumatic fever.
Research
The economic and health burdens of diseases caused by group A Streptococcus in New ZealandIn preparation for the future arrival of a group A Streptococcus (GAS) vaccine, this study estimated the economic and health burdens of GAS diseases in New Zealand. The annual incidence of GAS diseases was based on extrapolation of the average number of primary healthcare episodes managed each year in general practices (2014-2016) and on the average number of hospitalizations occurring each year (2005-2014). Disease incidence was multiplied by the average cost of diagnosing and managing an episode of disease at each level of care to estimate the annual economic burden.
Research
Rheumatic Heart Disease Control Programs, Registers, and Access to CareThis chapter outlines the evidence and evolution of RHD control programs and draws conclusions about priorities following the 2018 World Health Organization Global Resolution on rheumatic fever and RHD.